Condition: Infertility · Insemination · Sponsor: Centre Hospitalier Intercommunal Creteil
The aim of this study is to evaluate the use of a fixed dose of 3.66 mcg of follitropin delta (Rekovelle) on ovarian response during ovarian stimulation for intrauterine insemination (IUI). The assumption is that this fixed dose will be effective while minimizing the risk of multiple pregnancies. A recent study demonstrated the efficacy of follitropin delta for ovarian stimulation in IUI, and it has been approved in France for controlled ovarian stimulation in assisted reproductive techniques such as in vitro fertilization (IVF) and IVF with intracytoplasmic sperm injection (ICSI). With an adapted dose of Rekovelle for patients with regular menstrual cycles, ovarian stimulation is optimized from the first attempt, promoting the development of two follicles to improve pregnancy chances while reducing the risk of multiple pregnancies. This approach aims to achieve pregnancy faster and provide a more comfortable treatment experience.
This description comes directly from the study's public registry record.
Aroua Ben Guirat · +33157023710 · aroua.benguirat@chicreteil.fr
Always discuss trial participation with your own doctor first.
| Cabinet Dr Elodie Descat-Polyclinique Jean Villar | Bruges, France | Recruiting |
| Chi Creteil | Créteil, France | Recruiting |
| Cabinet Dr Géraldine PORCU-Institut de Médecine de la Reproduction | Marseille, France | Recruiting |
| Cabinet Dr Nicolas Chevalier-Centre AMP Saint Roch | Montpellier, France | Recruiting |
| Cabinet Dr Nathalie Massin- Hôpital Américain De Paris | Neuilly-sur-Seine, France | Suspended |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07153367